185 related articles for article (PubMed ID: 34761007)
1. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.
Liu Y; Cheng L; Huang W; Cheng X; Peng W; Shi D
J Immunol Res; 2021; 2021():2048833. PubMed ID: 34761007
[TBL] [Abstract][Full Text] [Related]
2. Genomic instability-related twelve-microRNA signatures for predicting the prognosis of gastric cancer.
Xu J; Song J; Chen X; Huang Y; You T; Zhu C; Shen X; Zhao Y
Comput Biol Med; 2023 Mar; 155():106598. PubMed ID: 36764156
[TBL] [Abstract][Full Text] [Related]
3. Development and verification of a manganese metabolism- and immune-related genes signature for prediction of prognosis and immune landscape in gastric cancer.
Han X; Leng C; Zhao S; Wang S; Chen S; Wang S; Zhang M; Li X; Lu Y; Wang B; Qi W
Front Immunol; 2024; 15():1377472. PubMed ID: 38807601
[TBL] [Abstract][Full Text] [Related]
4. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients.
Zhang C; Zhang CD; Ma MH; Dai DQ
World J Gastroenterol; 2018 Mar; 24(11):1206-1215. PubMed ID: 29568201
[TBL] [Abstract][Full Text] [Related]
5. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression.
Li CY; Liang GY; Yao WZ; Sui J; Shen X; Zhang YQ; Peng H; Hong WW; Ye YC; Zhang ZY; Zhang WH; Yin LH; Pu YP
Clin Transl Oncol; 2017 Feb; 19(2):162-172. PubMed ID: 27173517
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
[No Abstract] [Full Text] [Related]
7. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
[TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
9. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
10. Predictive and Prognostic Value of an MicroRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy.
Cheng X; Wei H; Zhang S; Zhang F
DNA Cell Biol; 2021 Nov; 40(11):1428-1444. PubMed ID: 34767733
[TBL] [Abstract][Full Text] [Related]
11. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
12. A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer.
Liu SJ; Yang YB; Zhou JX; Lin YJ; Pan YL; Pan JH
Dis Markers; 2021; 2021():2385406. PubMed ID: 34868391
[TBL] [Abstract][Full Text] [Related]
13. Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer.
Bao S; Hu T; Liu J; Su J; Sun J; Ming Y; Li J; Wu N; Chen H; Zhou M
J Nanobiotechnology; 2021 Jan; 19(1):22. PubMed ID: 33436002
[TBL] [Abstract][Full Text] [Related]
14. Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer.
Mei D; Qi Y; Xia Y; Ma J; Hu H; Ai J; Chen L; Wu N; Liao D
World J Surg Oncol; 2021 Oct; 19(1):311. PubMed ID: 34686186
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and the Immune Microenvironment in Gastric Cancer.
Wang F; Chen C; Chen WP; Li ZL; Cheng H
Biomed Res Int; 2021; 2021():6014202. PubMed ID: 34708125
[TBL] [Abstract][Full Text] [Related]
16. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
17. Upgrading the Repertoire of miRNAs in Gastric Adenocarcinoma to Provide a New Resource for Biomarker Discovery.
Pewarchuk ME; Barros-Filho MC; Minatel BC; Cohn DE; Guisier F; Sage AP; Marshall EA; Stewart GL; Rock LD; Garnis C; Lam WL
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739401
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
19. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression.
Ahadi A
IUBMB Life; 2020 May; 72(5):884-898. PubMed ID: 32078236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
